Compare XTNT & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | NEPH |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.9M | 49.4M |
| IPO Year | 2009 | 2004 |
| Metric | XTNT | NEPH |
|---|---|---|
| Price | $0.32 | $3.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $1.03 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 185.7K | 34.0K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 125.00 | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | ★ $53,337,000.00 | $18,789,000.00 |
| Revenue This Year | N/A | $17.81 |
| Revenue Next Year | $10.85 | $15.90 |
| P/E Ratio | ★ N/A | $28.88 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.27 | $2.66 |
| 52 Week High | $0.95 | $6.42 |
| Indicator | XTNT | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 39.52 |
| Support Level | $0.32 | $3.19 |
| Resistance Level | $0.49 | $3.78 |
| Average True Range (ATR) | 0.02 | 0.31 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 34.57 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.